Skip to main content
VTRS
NASDAQ Life Sciences

Viatris Completes €650M Senior Notes Offering to Refinance 2026 Debt

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$15.37
Mkt Cap
$17.899B
52W Low
$8.625
52W High
$17.53
52W Position info
78% above low
Off High info
12% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

VTRS sits 78% above its 52-week low of $8.625 on elevated volume (2.0× avg).

Summary

Viatris Inc. completed a €650 million Senior Notes offering due 2033 at 4.250% interest, primarily to refinance $1.675 billion of existing debt maturing in 2026.


Key Events · Financing and Capital Events · VTRS

  • Senior Notes Offering Completed

    Viatris Inc. completed a public offering of €650,000,000 aggregate principal amount of its 4.250% Senior Notes due 2033 on June 17, 2026. This finalizes the terms and pricing of the offering initiated on June 12, 2026.

  • Debt Refinancing

    The net proceeds from the offering are primarily intended to repay the entire $1.675 billion outstanding principal amount of 3.950% Senior Notes due 2026, extending the company's debt maturity profile.

  • Guaranteed by Subsidiaries

    The new Senior Notes are senior unsecured obligations of Viatris and are guaranteed on a senior unsecured basis by Mylan Inc., Mylan II B.V., and Utah Acquisition Sub Inc.


Analysis · VTRS · Life Sciences

This 8-K filing confirms the successful completion of Viatris's €650 million Senior Notes offering, which was previously announced and priced. The proceeds will be used to refinance a significant portion of existing debt maturing in 2026, extending the company's debt maturity profile. This is a standard liability management action that strengthens the company's financial flexibility by addressing upcoming maturities.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VTRS was trading at $15.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.9B. The 52-week trading range was $8.63 to $17.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VTRS - Latest Insights

VTRS
Nov 12, 2026, 4:16 PM EST
Filing Type: SC TO-T/A
Importance Score:
7
Price at Filing: $20.69
Real-time Price: $20.90 info
Change: +$0.2104 (+1%) info
Market Cap: $23.869B info
VTRS
Nov 05, 2026, 9:23 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.40
Real-time Price: $20.90 info
Change: +$1.50 (+8%) info
Market Cap: $23.869B info
VTRS
Nov 05, 2026, 7:45 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.33
Real-time Price: $20.90 info
Change: +$1.57 (+8%) info
Market Cap: $23.869B info
VTRS
Nov 05, 2026, 6:59 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.36
Real-time Price: $20.90 info
Change: +$1.54 (+8%) info
Market Cap: $23.869B info
VTRS
Oct 30, 2026, 7:40 AM EDT
Filing Type: SC TO-T
Importance Score:
8
Price at Filing: $19.30
Real-time Price: $20.90 info
Change: +$1.60 (+8%) info
Market Cap: $23.869B info